J3R-MC-YDAN
Research type
Research Study
Full title
A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants with Osteoarthritis Knee Pain, and Obesity or Overweight (ENLIGHTEN-4.
IRAS ID
1013362
Contact name
Emily Coss
Contact email
Sponsor organisation
Eli Lilly and Company
Clinicaltrials.gov Identifier
Research summary
Short title of this project: : Efficacy and Safety of Eloralintide in Participants with Osteoarthritis Knee Pain and Obesity or Overweight
The ENLIGHTEN-4 study is a clinical research project designed to test whether a new investigational medicine can help reduce body weight in people with obesity or those who are overweight and suffer from Osteoarthritis Knee Pain. Many factors can affect body weight, not just diet or activity levels. Lowering body weight may help reduce the risk of certain health problems and improve overall health.
Participants in this study will receive either the investigational medicine or a placebo (a substance with no active medicine). Neither the participants nor the study team will know which treatment each person is receiving. All participants will have access to specialised doctors and researchers, advice on nutrition and physical activity, and regular health checks. The study involves clinic and telehealth visits over a period of about 1 to 2 years. During these visits, participants will have health checks, blood and urine tests, and receive support for healthy lifestyle changes. Participants will also be trained to give themselves the study medicine as an injection once a week.
About 900 participants will take part in this study, of which approximately 61 will be recruited from the UK. By taking part in this study, participants are helping researchers learn more about potential new treatments for obesity and overweight with people who suffer from Osteoarthritis Knee Pain which could benefit many people in the future.REC name
London - Central Research Ethics Committee
REC reference
26/LO/0094
Date of REC Opinion
19 Mar 2026
REC opinion
Further Information Favourable Opinion